Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Invivyd, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
25.4
53.4
Research and development
183
179
159
137
38.3
Selling, general and administrative
36.5
47
49.1
63.4
66.9
Operating expenses
227
248
213
202
109
Operating income
-227
-248
-213
-177
-55.6
Other non-operating income
0.12
6.71
14.1
6.95
3.07
Income tax
0
0
0
0
0
Net income
-38.7
-83.4
-144
-227
-241
-199
-170
-52.5
EBITDA
-227
-248
-212
EPS, basic
-5.32
-2.23
-1.81
-1.43
-0.30
EPS, diluted
-5.32
-2.23
-1.81
-1.43
-0.30
Shares, basic (weighted)
0.13
20.3
42.6
108
110
119
172
Shares, diluted (weighted)
0.13
20.3
42.6
108
110
119
172
Balance sheet
FY2021
FY2021
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
91.2
393
478
542
92.1
201
69.3
227
Receivables
0
10.9
13.9
Inventory
0
25.9
Other current assets
0.26
0.58
1.52
4.93
24.2
3.73
6.86
Total current assets
396
680
617
377
225
101
247
Property, plant and equipment
0.08
2.28
1.9
1.51
1.37
Lease right-of-use assets
0
3.78
2.23
1.39
2.44
Other non-current assets
6.12
3.3
0.19
0.18
0.03
0.11
Total assets
398
686
620
383
229
130
277
Accounts payable
10.7
17.6
5.78
1.52
7.95
10.4
13.7
Accrued liabilities
27.2
35.5
56.3
21.9
40.9
50.2
19.1
Total current liabilities
37.9
53
62.1
25
50.3
62
34.2
Lease liabilities
0
2.17
0.72
0
1.18
Other non-current liabilities
0.01
0
0.7
0
Total liabilities
37.9
53.1
62.1
27.2
51.7
62
35.3
Paid-in capital
4.07
842
850
890
910
970
1,196
Retained earnings
-149
-209
-292
-533
-732
-902
-954
Treasury stock
0
0
0
0
Other comprehensive income
0
-0.01
-0.27
-0.01
-0.01
-0.04
Shareholders' equity
-103
-145
633
558
356
177
67.5
242
Total equity
-103
-145
633
558
356
177
67.5
242
Total liabilities and equity
398
686
620
383
229
130
277
Shares outstanding
0
5.6
111
111
109
110
120
282
Cash flow statement
FY2021
FY2021
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-38.7
-83.4
-144
-227
-241
-199
-170
-52.5
Depreciation and amortization
0
0.04
0.48
Stock-based compensation
17.8
21.6
18.7
19.8
11.6
Change in receivables
0
-10.9
-3.34
Change in inventory
0
-24.9
-0.37
Change in payables
-2.37
-4.3
6.47
2.42
3.21
Cash from operations
-185
-220
-173
-170
-58.1
Capital expenditures
-0.08
-1.71
-0.62
-0.14
-0.16
Purchases of investments
-189
-298
-91.2
0
Sales and maturities of investments
138
69
373
0
Cash from investing
-50.7
-231
281
-0.14
-0.16
Stock issued
331
0.27
0.24
0.22
0.25
Share buybacks
0
-0
-0
0
Cash from financing
663
0.51
1.05
39.3
216
Net change in cash
427
-450
109
-131
157
Free cash flow
-185
-222
-174
-171
-58.3
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.93 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-192.8%
Operating income / revenue.
Net margin
-183.9%
Net income / revenue.
FCF margin
-187.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-185.8%
Cash from operations / revenue.
Return on equity (ROE)
-59.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-49.0%
Net income / average total assets.
Return on invested capital (ROIC)
-423.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
134.0%
Research and development expense / revenue.
SG&A / revenue
151.1%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
19.2%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.1%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
110.5%
Revenue vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
257.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-12.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
113.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-10.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
45.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
16.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
5.87x
Current assets / current liabilities.
Quick ratio
5.52x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
5.16x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.18
Revenue / diluted weighted shares.
FCF per share
-$0.34
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.34
Cash from operations / diluted weighted shares.
Book value per share
$0.61
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
4.72x
Market cap / revenue.
P/B
1.52x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.52x
Market cap / tangible book value, when positive.
EV/Sales
1.98x
Enterprise value / revenue.
FCF yield
-39.8%
Free cash flow / market cap.
Earnings yield
-39.0%
Net income / market cap (the inverse of P/E).
What was Invivyd, Inc.'s revenue in fiscal 2025?
Invivyd, Inc. reported revenue of $53.4M for fiscal 2025, 110.5% higher than the year before.
Was Invivyd, Inc. profitable in fiscal 2025?
No. It reported a net loss of $52.5M.
How much free cash flow did Invivyd, Inc. generate in fiscal 2025?
Cash from operations of $58.1M minus capital expenditures of $155.0K left free cash flow of -$58.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.